,16,20,21 Mepolizumab, the first-in-class anti–IL-5 humanized mAb, became available to patients with EGPA in the United States in 2017,22,23 followed by benralizumab in 2024.24 The gene discussed is IL5; the disease is eosinophilic granulomatosis with polyangiitis.